News | April 12, 2026
EMA gives green light to warmer & simpler delivery rules for Wegovy injection
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
Safety was equally impressive. ENV-294 was well tolerated
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
